ReviewInflammation research : official journal of the European Histamine Research Society ... [et al.]2025
TREM2-driven peripheral macrophage regulation in inflammatory diseases: implications extending beyond neurological disorders.
Review in Inflammation research : official journal of the European Histamine Research Society ... [et al.], 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Assessing the Clinical Relevance of Blood Soluble Triggering Receptor Expressed on Myeloid Cells 2 in Neurological Diseases.The European journal of neuroscience · 2026Observational
- The role of DAP12 in immune-related inflammatory diseases.Inflammation research : official journal of the European Histamine Research Society ... [et al.] · 2026Review
- Epidemiological Trends and Shared Molecular Signatures of Pancreatic Ductal Adenocarcinoma and Diabetes: An Integrative Analysis Based on Global Burden of Disease and Gene Expression Omnibus Datasets.Journal of Cancer · 2026Article
- Article
- Circadian immunoregulation in cutaneous wound healing: from immune cell temporal heterogeneity to chronotherapeutic strategies.Frontiers in immunology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Triggering receptor expressed on myeloid cells 2 (TREM2), a crucial immunomodulatory receptor expressed on myeloid cells, is pivotal in regulating immune responses and maintaining tissue homeostasis. TREM2 has gained prominence as a key factor in deciphering the pathological mechanisms of diverse diseases, particularly due to its significant influence on macrophage function in disease progression. The TREM2 signaling pathway governs macrophage activation, polarization, phagocytosis, and cytokine secretion, thereby impacting immune regulation and the progression of inflammation. Dysregulation of TREM2-mediated macrophage function is closely linked to the pathogenesis of multiple systemic diseases. Specifically, in the central nervous system, extensive research has focused on TREM2's regulatory influence on microglial function. Concurrently, its pathogenic roles in disorders beyond the neurological spectrum have increasingly garnered investigative attention. This review offers a structured overview of recent advances in understanding the mechanisms through which TREM2 regulates macrophage function and its implications in non-neurological diseases. Particular emphasis is placed on the potential of TREM2 as a therapeutic target for modulating macrophage-mediated pathological processes.
Indexed as
Identifiers
41408002What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.